8-K: Nexalin Technology Executes 1-for-30 Reverse Stock Split

Nexalin Technology, Inc. announced a 1-for-30 reverse stock split of its common stock, effective August 28, 2026, to comply with Nasdaq's bid-price rule.

Summary

• Nexalin Technology, Inc. has implemented a 1-for-30 reverse stock split for its common stock.
• This action was taken to ensure continued compliance with the Nasdaq bid-price rule.
• The reverse stock split became effective on August 28, 2026, at 5:00 p.m. Eastern Time.
• The company's common stock is expected to trade on a split-adjusted basis starting August 31, 2026.
• No fractional shares will be issued; instead, cash payments will be made for fractional entitlements.
• The new CUSIP number for the common stock will be 65345B300.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as a reverse stock split is often a sign of a company struggling to maintain compliance with exchange listing requirements, potentially indicating underlying financial or operational challenges.

Positives

• Maintains listing on The Nasdaq Capital Market by addressing the bid-price rule.
• Stockholders previously approved future reverse stock splits, indicating prior consent for such actions.

Negatives

• A reverse stock split is often a signal of a company's stock price falling below exchange minimums, suggesting potential underlying business challenges.
• The need for a reverse split indicates the company has not been able to organically increase its stock price to meet listing requirements.
• Cash payments for fractional shares may represent a small cash outflow for the company.

Risks

• Failure to maintain compliance with Nasdaq listing rules could lead to delisting.
• The reverse stock split may not address the underlying reasons for the low stock price, potentially leading to continued price declines.
• Investor perception of reverse stock splits can be negative, potentially impacting future stock performance.

Future Outlook

The filing does not contain specific forward-looking financial guidance but focuses on the operational and compliance aspects of the reverse stock split. The company's business strategy involves developing neurostimulation products for mental health disorders.

Management Comments

• The Company announces that its board of directors has approved a 1-for-30 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule.
• The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common tactic for companies, particularly in the biotechnology and technology sectors, to regain compliance with exchange listing requirements like the minimum bid price. However, it is often viewed as a cosmetic fix that does not address underlying business performance issues.

Comparison to Industry Standards

• Many small-cap and micro-cap companies, especially in the biotech and tech sectors, undertake reverse stock splits to maintain Nasdaq or NYSE listing. For example, companies like Sorrento Therapeutics (SRNE) and Cassava Sciences (SAVA) have previously implemented reverse splits.
• The 1-for-30 ratio is a significant adjustment, suggesting the stock price was considerably below the $1.00 minimum threshold required by Nasdaq.
• The primary goal is to meet the $1.00 minimum bid price requirement, a standard for continued listing on major exchanges.

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares reduced by a factor of 30, with a corresponding increase in the price per share, though their overall equity value is not immediately changed by the split itself.
• Shareholders entitled to fractional shares will receive a cash payment instead.
• The Nasdaq Capital Market will continue to list the company's stock, provided the reverse split successfully maintains compliance.

Next Steps

• The common stock will trade on a split-adjusted basis starting August 31, 2026.
• Cash payments will be made to stockholders entitled to fractional shares.
• The company will continue to operate its business focused on neurostimulation products for mental health.

Key Dates

Recommendation

The reverse stock split is a necessary measure to maintain Nasdaq listing but does not fundamentally improve the company's business prospects or profitability. While it prevents immediate delisting, it does not guarantee future stock price appreciation and is often viewed negatively by the market. Therefore, a 'hold' recommendation is appropriate pending further positive developments in the company's core business operations.

Keywords

Reverse Stock Split, Nasdaq Compliance, Bid-Price Rule, Common Stock, Corporate Action, Stock Adjustment